Ti trovi qui: Home » International news

Three Unimore professors in the Medicine Maker Power List 2019

The number of Unimore researchers is increasingly growing in world’s scientific journals. This year, the Medicine Maker list includes three professors of the University of Modena and Reggio Emilia, which is therefore the most represented Italian University.

A world leading publication in cell and gene therapy, the Medicine Maker has updated its list with the 100 best leaders and opinion makers in the world who have carried out a project able to change the life in the Biopharmaceutical industry, and therefore to help thousands of people all over the world with their revolutionary scientific findings.

The Medicine Maker Power List 2019 supervises eligible candidates all over the world by means of a group of experts in charge of assessing the activities carried out in the sector, the visibility and the number of references to scientific articles written by the authors, and draws up a list divided into four categories as follows: Industry InfluencersBusiness CaptainsMaster of the BenchChampions of Change.

The Champions of Change list includes Professor Massimo Dominici of the Department of Medical and Surgical Sciences for Mother and Infant, and the Adult, and Responsible for the Research Laboratories of the Mother and Infant Department of the University Hospital of Modena, whereas for the second subsequent year, the Master of the Bench list includes Professor Michele De Luca and Professor Graziella Pellegrini of the “Stefano Ferrari” Regenerative Medicine of Unimore.

This further ranking – Unimore Rector, Professor Angelo O. Andrisano underlines – is the evidence that our University gathers internationally renowned innovative research in the medical and pharmaceutical field. To our colleagues De Luca, Dominici and Pellegrini I would like to express my personal satisfaction, and on behalf of the University, for this deserved result that rewards their efforts to give sick people hope”.

Michele De Luca

A graduate in Medicine and Surgery, Michele De Luca is an ordinary professor of biochemistry and directs the “Stefano Ferrari” Centre of Regenerative Medicine and the Stem Cell and Regenerative Medicine Interdepartmental Centre of Unimore. De Luca was the first researcher in Europe who more than twenty years ago applied epidermal stem cells for healing severe burns, and is considered one of the main scientists at international level in the study of biology of epidermal stem cells for clinical applications. A real pioneer both in cell and gene therapy, he anticipated everybody on the chance to reproduce in vitro and transfer to the clinic many coating epithelia. He is the author of the first world experimentation of ex-vivo gene therapy for the treatment of Epidermolysis Bullosa or “Syndrome of Butterfly Children”, and coordinates various research projects, both national and international, for implementing gene therapy protocols also to other forms of Epidermolysis Bullosa.

Massimo Dominici

He was born in Lodi in 1972. In 1996, he graduated with honours in Medicine and Surgery in Pavia. He carried out an internship at the Institution of Haematology of the University of Wien (Austria). In 2000, he specialised in Haematology with Honours at the University of Ferrara and then became PhD Fellow at the Jude Children’s Research Hospital of Memphis (USA). In 2005, he worked as university researcher in the Medical Oncology Department of UNIMORE and was in charge of the Laboratory of Cell Therapies. Since 2005, he has been working as an affiliated Medical Director at the complex Structure of Oncology. Since 2007, he has been Tutor of the PhD School of Molecular and Regenerative Medicine. In November 2015 and 2016, he became Associate Professor in Medical Oncology and Director of the Specialisation School in Oncology, respectively. He has the national qualification of Full Professor in Medical Oncology. He is a founder and scientific project head of the laboratory of biocompatibility of the Mirandola Technopole. He is the author of over 140 manuscripts, 2 books, 3 book chapters with around 20000 references. He has been invited to participate in over 150 seminars. He carried out twenty-seven financed research projects, and 12 patents. He is the founder of the university start-up Rigenerand srl. He is a member of several national and international scientific companies, as well as of boards in Medical and Scientific Foundations, and no-profit associations.  He has been appointed first non-US president of the International Society for Cell and Gene Therapy - ISCT (2014-16). He is the editor and reviewer for international journals and public and private entities for research financing.  

Graziella Pellegrini

A graduate in Chemistry and Pharmaceutic Technologies and in Pharmacy, Graziella Pellegrini is a full professor of applied biology and coordinates the cell therapy at “Stefano Ferrari” Centre of Regenerative Medicine.  An internationally renowned researcher in translational medicine, she has developed clinical protocols for the treatment of stable vitiligo an piebaldism through the co-colture of various cell types. The most important scientific result achieved was the identification and characterisation of stem cells of human corneal epithelium, and the definition, in collaboration with ophthalmologist colleagues, of clinical protocols that today make it possible a consolidated therapy for the treatment of blindness caused by the destruction of the cornea as a consequence of chemical burns through cultivated epithelial stem cells. This type of therapy has revolutionised the therapeutic approach of chemical burns of the ocular surface and has now well established in different Countries at global level. In 2015, it has obtained the conditional approval of EMA for being marketed under the Holoclar® trademark.

Categorie: International - english

Articolo pubblicato da: Ufficio Stampa Unimore - ufficiostampa@unimore.it